Psychedelic Therapy Legality Map

Legality tells you whether a door exists; access is whether you can walk through it. For 31 countries, this page answers both — route by route, with criteria, costs and primary sources. However, a legal pathway existing does not mean it’s right for you, and «decriminalized» does not mean legal. Check contraindications before geography.

Review date: 18 August 2026 Methodology Sources

Violet Regulated pathway — a regulated pathway exists (always with conditions).
Yellow Narrow access — access exists but is narrow: case-by-case programs, hospital-only, single states, or decriminalization without legal supply.
Pink Research only — no lawful access outside research, or status being verified.

Where psychedelic therapy is most accessible

Esketamine (Spravato) access worldwide

The EMA’s centralized authorization (18 December 2019) legally covers every EU/EEA member — so Greece, Croatia, Hungary, Romania, Bulgaria, Slovakia, Slovenia, the Baltics, Luxembourg, Cyprus, Iceland and Liechtenstein all formally have esketamine approved. However, national reimbursement and clinical availability vary widely. Beyond Europe, approval has expanded globally with real differences in access and practice.

Country	Status	Note
🇨🇳 China	Approved 2023 (NMPA)	Only for depression with acute suicidal ideation — the TRD trial failed; launched 2025, hospital-only
🇯🇵 Japan	NOT approved	The Japanese Phase 2b failed — clinics openly state it is unapproved; off-label IV-ketamine clinics exist instead
🇰🇷 South Korea	Approved 2020 — contested	Regulator demanded Korean efficacy data (2024) to keep the authorization
🇹🇼 Taiwan	Approved 2021 (TFDA)	TRD + suicidality; supervised use at certified centers, active private-clinic scene
🇸🇬 Singapore	Approved 2020 (HSA)	Hospital-only (SGH, IMH); no private ketamine-clinic market
🇮🇱 Israel	Registered ~2020-21	Dense clinic + research scene (real-world cohort studies); an MDMA/PTSD Phase 2 trial is recruiting
🇦🇪 UAE / 🇸🇦 Saudi / 🇹🇷 Turkey	Registered	Active clinical use in UAE (Dubai/Abu Dhabi clinics); SFDA and TİTCK registrations confirmed
🇦🇷 Argentina / 🇨🇱 Chile / 🇨🇴 Colombia	Approved 2020-21	ANMAT / ISP / INVIMA; Argentina also runs IV ketamine in public hospitals under published protocols
🇮🇳 India	No esketamine	But psychiatrist-led off-label ketamine clinics operate (Schedule X regime)
🇺🇦 Ukraine	Not registered	See the Ukraine panel — the ketamine-therapy story runs on racemic ketamine, not Spravato

Psychedelic Substances: Access & Status in 31 countries

Beyond classic compounds: ayahuasca, ibogaine, LSD and their status

Jurisdiction	Ayahuasca	Ibogaine	LSD
🇨🇭 Switzerland	—	—	Exceptional license (Art. 8)
🇺🇸 United States	Religious exemptions only	Schedule I — research momentum	—
🇧🇷 Brazil	Religious use legal — landmark framework	Unscheduled, unregistered — case-by-case tolerance	—
🇵🇪 Peru	Traditional use legal — cultural heritage	—	—
🇨🇷 Costa Rica	Unscheduled — narrowing gray zone	Unscheduled — covered by 2025 warning	—
🇲🇽 Mexico	Unscheduled — gray zone, enforcement risk	Not scheduled — clinics operate	—
🇿🇦 South Africa	—	Schedule 6 prescription substance	—
🇳🇿 New Zealand	—	Prescription medicine since 2010	—

Substance coverage roadmap

A global legality map is only as good as its verification. Covered to full standard now: esketamine, ketamine, psilocybin, MDMA, medical cannabis, ayahuasca, ibogaine (+ LSD where a legal route exists — Switzerland).

Updates coming soon: legal landscape for

5-MeO-DMT
DMT
LSD
Mescaline, peyote, San Pedro
2 °C-B, kambo, salvia

Clinical trials: the door that’s open everywhere

In every country on this page — including those where psilocybin and MDMA are strictly illegal — one legal route always exists: participating in a clinical trial. It is both the most underused option and the most misunderstood one.

How trials actually work. A clinical trial tests a treatment under a research protocol approved by an ethics committee and the national regulator. Phase 1 tests safety (often in healthy volunteers), Phase 2 tests whether the treatment works, Phase 3 confirms it at scale — patient trials for depression, PTSD or anxiety are usually Phase 2 or 3. Participation is always free: study procedures, the substance and the accompanying therapy cost you nothing, and travel reimbursement is common. Patient trials do not pay you for participation — and that cuts both ways: anyone charging money for «trial access» is running a scam. Expect strict screening (psychiatric and medical history, current medications, contraindications — a personal or family history of psychosis or bipolar disorder excludes you from most classic-psychedelic studies), the possibility of a placebo arm, structured questionnaires, and scheduled follow-up. Screening takes weeks and enrollment is never guaranteed — a trial is a real option, not a bookable service.

How to find one. The global registry is ClinicalTrials.gov — search by condition, substance and country, filter for «recruiting», read the eligibility criteria, then contact the study team with a written treatment history (it does more work than anything you say in the room). Each country panel above lists its trial scene and recruiting highlights. Two honest caveats: trials are designed around research questions, not your treatment plan — you may receive a placebo, and the study ends when the protocol ends; and while trials are the one route genuinely open to suitable candidates from further away, most visits are in-person and travel is usually self-funded.

«Phase 3» is not the same as «you can join.» Several headline programs have already closed enrollment (Compass COMP360, Usona’s uAspire, the BPL-003 pivotal) — a program can be advanced and closed at the same time. Recruiting statuses on this page were verified against the ClinicalTrials.gov API on 30 July 2026 and are refreshed on the monthly cycle; the largest multi-country recruiting program right now is Cybin’s CYB003 Phase 3 (sites in AU, CZ, DE, GR, IE, PL, UK, US).

Frequently asked questions

Where is psilocybin therapy fully legal in 2026?

Through a national medical framework: Australia (since July 2023, TGA-authorised psychiatrists) and the Czech Republic — where the law took effect on 1 January 2026 but, per NUDZ's official statement, treatment delivery had not started as of March 2026 and is expected in the second half of 2026. Through state programs in the US: Oregon, Colorado, Utah (pilot) and New Mexico. Germany runs a two-site compassionate use program (confirm current status — the initial listing period ended 11 July 2026), Switzerland a physician-gated exceptional-license program. The Netherlands allows legal psilocybin truffles without a medical framework.

Which countries reimburse esketamine (Spravato)?

Publicly funded routes run in Germany, the Netherlands, Poland, Switzerland, Belgium, Italy, Ireland, Spain, Finland, Czechia, Portugal, Denmark and Scotland — each with its own criteria (typically two to four documented failed treatments; see the country panels). England and Wales are private-only (NICE declined), France is hospital-only, Sweden advises "strongly restrained" use with region-by-region funding, Austria funds inpatient with case-by-case outpatient approval, and Norway rejected Spravato — while becoming the first country to publicly fund generic IV ketamine instead.

Is ketamine therapy legal?

In every country on this page, yes — ketamine is a licensed medicine that doctors can use off-label. What differs is the delivery model: private clinic markets (UK, Germany, Switzerland, Spain, Poland, Norway, Sweden, Czechia), hospital-only systems (France, Belgium, Netherlands, Finland), and one world-first public funding of generic IV ketamine (Norway, since August 2025). A note on terms: ketamine and esketamine are dissociative anesthetics, not classic psychedelics — they sit in this guide because they are the most accessible medicines in psychedelic-adjacent therapy.

Does "decriminalized" mean I can legally buy or use psychedelics?

No. Decriminalization (e.g., Portugal's Law 30/2000, which covers personal possession of all drugs) only means small personal possession is not prosecuted as a crime. Supply remains illegal, there is no quality control, and no legal therapy framework. It is a harm-reduction policy, not an access pathway.

Is MDMA therapy legal anywhere?

Australia has the only standing national pathway (TGA-authorised psychiatrists, PTSD, since July 2023). In Europe, Switzerland is the single legal route: exceptional physician licenses under Article 8 of the Narcotics Act, in use since 2014 — about 100 authorized physicians treated 723 patients across the program in 2024. Canada allows case-by-case Special Access requests. In the US, the FDA declined the first application in August 2024 and the process is ongoing.

Is ayahuasca legal anywhere?

Yes — but as religion and tradition, not medicine. Brazil's CONAD framework has recognised religious and ritual use since 1987 (codified in Resolution 01/2010, which explicitly prohibits ayahuasca tourism and commercial use), and Peru declared traditional ayahuasca use part of its National Cultural Heritage in 2008. In the US, two church exemptions stand after court rulings (UDV, 2006 Supreme Court; Santo Daime, 2009). Costa Rica is an unregulated gray zone with a January 2025 health-ministry warning; Mexico bans ayahuasca despite open retreat marketing; the Netherlands (2019) and Italy (2022) banned it. Nowhere is ayahuasca a licensed medical treatment.

Where is ibogaine legal, and is it safe?

Legal routes exist in New Zealand (a non-approved prescription medicine since 2010), Brazil (prescription, case-by-case) and — as an unscheduled substance — Mexico, where most of the world's ibogaine clinics operate. Safety is the bigger question than legality: ibogaine carries serious cardiac risk (QT prolongation, documented deaths in unscreened settings), so ECG screening, cardiac monitoring and medical staffing are non-negotiable wherever you are. In the US it remains Schedule I, but Texas funded $50M of FDA-supervised trials in 2025 — the research door is opening formally.

How do I join a clinical trial, and does it cost anything?

Search ClinicalTrials.gov by condition, substance and country, filter for "recruiting", read the eligibility criteria, then contact the study team — a written treatment history speeds everything up. Participation is always free (procedures, substance and accompanying therapy included; travel reimbursement is common), but trials never pay patients for taking part — anyone charging money for "trial access" is running a scam. Expect strict screening, a possible placebo arm, and no guarantee of enrollment.

Something is legal in my country — does that mean it's safe for me?

No. Legality and safety are different questions. Contraindications — including a history of psychosis or bipolar disorder, certain heart conditions and some medications — apply regardless of jurisdiction. Start with our self-check and safety basics before thinking about geography.

Methodology & updates

Every status is built the same way: the primary source first — the regulator’s own decision or register, the legislation itself, or the trial’s ClinicalTrials.gov entry — then a cross-check against the leading independent trackers, Psychedelic Alpha’s worldwide laws tracker and Blossom’s country reports, which we treat as the reference layer: where our reading and a tracker disagree, we resolve to the primary source and flag the discrepancy rather than publish around it. Cannabis statuses are sourced separately — from the EUDA (the EU drugs agency) and specialized cannabis policy research, not psychedelic trackers, because that field has its own authoritative projects.

Since the July 2026 deep-verification pass, statuses follow a two-source rule: one government-linked source from the country itself (regulator, register, gazette, law text) plus one independent reputable source — and where law and street reality diverge (Thailand, Spain, South Africa, Costa Rica, Mexico), the panel says both, explicitly: on paper / on the ground. Statuses we have not yet verified to this standard are published as «being verified», not guessed. Program facts carry dates because this field moves; time-limited programs are flagged explicitly. We re-verify the full page quarterly and after major regulatory events — the review date and next scheduled review are shown at the top — and every status is checked against our own legal counsel’s country memoranda before publication. Found an error or a change we missed? Tell us — corrections are part of how this page earns trust.

A note on terms: ketamine and esketamine are dissociative anesthetics, not classic psychedelics. They appear here because they are the most accessible medicines in psychedelic-adjacent therapy — and because esketamine (an approved medicine with a label and reimbursement rules) and off-label ketamine follow different regulatory regimes, we show them as separate routes.

Primary regulators and registries first; the leading independent trackers as the cross-check layer. Every country panel carries its own inline source links; this is the consolidated register.

Psychedelic Therapy Legality Map

Where are you?

Where psychedelic therapy is most accessible

Germany

Czech Republic

United Kingdom

Netherlands

Esketamine (Spravato) access worldwide

Psychedelic Substances: Access & Status in 31 countries

Beyond classic compounds: ayahuasca, ibogaine, LSD and their status

Substance coverage roadmap

Clinical trials: the door that’s open everywhere

Frequently asked questions

Methodology & updates

Sources

Where are you?

Where psychedelic therapy is most accessible

Germany

Czech Republic

United Kingdom

Netherlands

Esketamine (Spravato) access worldwide

Psychedelic Substances: Access & Status in 31 countries

Beyond classic compounds: ayahuasca, ibogaine, LSD and their status

Substance coverage roadmap

Clinical trials: the door that’s open everywhere

Frequently asked questions

Methodology & updates

Sources

The most important conversations shaping the future of psychedelics, delivered weekly.

Sign in to your account

The most important conversations shaping the future of psychedelics, delivered weekly.